Products with Anti-hyperlipidemic bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN5958 | Puerarin |
| Puerarin is a 5-HT2C receptor and benzodiazepine site antagonist, it exerts a regulatory effect on lipid accumulation by decreasing lipogenesis in hepatocytes, it may have therapeutic benefits in the treatment of fatty liver and lipid-related metabolic disorders, it also may act as an intracellular ROS scavenger, and its antioxidant properties may protect against Abeta25-35-induced cell injury,and apoptosis and could also promote the survival of PC12 cells. | |
| BCN5960 | Astragaloside IV |
| Astragaloside IV can protect the myocardium against ischemia/reperfusion injury, inhibit adenovirus replication and apoptosis in A549 cells in vitro, has anti-fibrotic effect against systemic sclerosis, and may be useful in ameliorating food-induced metabolic syndrome and membranous nephropathy. It suppresses the activation of ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2, (MMP)-9 in MDA-MB-231 breast cancer cells. | |
| BCN6215 | Globularin |
| 1. Globularin has hypoglycaemic and hypolipidemic activities in normal and streptozotocin-induced diabetic rats. | |
| BCN6241 | Cinnamaldehyde |
| Cinnamaldehyde has vasodilator, anti-melanoma, hypoglycemic, hypolipidemic, and anticancer effects, it possesses anti-bacterial activity against both gram-positive and gram-negative bacteria. Cinnamaldehyde has toxicity and antifeedant activities against the grain storage insects, Tribolium castaneum (Herbst) and Sitophilus zeamais Motsch. Cinnamaldehyde inhibited the expression of VEGF and HIF-α.Cinnamic aldehyde, a COX-2 inhibitor, exhibits cardioprotective, antidepressant-like, anti-leukemia, anti-oxidative and anti-inflammatory properties. Its supplementation can improve glucose and lipid homeostasis in diabetic animals. | |
| BCN6272 | Diosgenin |
| Diosgenin possesses antivascular calcification , anti-osteoclastogenesis, anti-inflammatory and anticancer properties, it has favorable effects in the improvement of diabetes and regulation of lipid metabolism. Diosgenin treated inflammation-related disorders through the blockade of cAMP, PKA, cPLA2, PAK, Akt and MAPKs signaling pathways. Diosgenin may decrease the risk of developing dementia of opiate abusers with HIV infection and the ApoE4 allele. | |
